←
Misako Nagasaka111 posts
Misako Nagasaka avatar✓

Misako Nagasaka ✓

@MNagasaka

Thoracic Oncologist at University of California Irvine

◷ Joined March 2014▧ 6 Photos and videos
CancerTherapyAdvisor avatar
⟳ Misako Nagasaka retweeted
CancerTherapyAdvisor@CancerTherAdvsr·Sep 15

The PALOMA-2 trial presented by @MNagasaka at #WCLC26 found amivantamab plus lazertinib had clinically meaningful and durable antitumor efficacy for #NSCLC 🫁 Dr Nagasaka spoke with us about the PALOMA-2 trial; see the data and read the article here🔽 bit.ly/4Ajvt5K

0:05
DAVA Oncology avatar
⟳ Misako Nagasaka retweeted
DAVA Oncology@DAVAOnc·Jul 9

At #DAVALung, Dr. @MNagasaka @UCIrvineHealth presented Taletrectinib TRUST-I/II pooled data: TKI-naïve cORR89.8%, DOR 49.7m, PFS 46.1m; TKI-pretreated cORR55.8%, DOR 16.6m, PFS 9.7m. No new safety signals with longer follow-up.

Post attachmentPost attachmentPost attachmentPost attachment
IDEOlogy Health avatar
⟳ Misako Nagasaka retweeted
IDEOlogy Health@IDEOlogyHealth·19 Oct 2025

IDEO Xchange: OptiTROP‑Lung04 - Sac-TMT demonstrated significantly better PFS and OS vs platium-based chemotherapy in post‑EGFR‑TKI NSCLC. How do you rate its clinical impact?

IDEOlogy Health avatar
⟳ Misako Nagasaka retweeted
IDEOlogy Health@IDEOlogyHealth·19 Oct 2025

IDEO Xchange: What percentage of your new patients in 1L EGFRm mNSCLC still receive osimertinib monotherapy?

IDEOlogy Health avatar
⟳ Misako Nagasaka retweeted
IDEOlogy Health@IDEOlogyHealth·19 Oct 2025

IDEO Xchange: How do you currently view the risk/benefit profile for combination regimens in treatment intensification in 1L EGFRm mNSCLC

IDEOlogy Health avatar
⟳ Misako Nagasaka retweeted
IDEOlogy Health@IDEOlogyHealth·19 Oct 2025

IDEO Xchange: Given the FLAURA2 exploratory analysis showing that osimertinib plus chemo improved OS across all major poor-prognosis subgroups, how likely are you to use the combination therapy as standard first-line treatment in these populations?

IDEOlogy Health avatar
⟳ Misako Nagasaka retweeted
IDEOlogy Health@IDEOlogyHealth·19 Oct 2025

IDEO Xchange: Phase III HARMONi‑6 shows ivonescimab + chemo outperformed tislelizumab + chemo in first‑line squamous NSCLC, with superior PFS and comparable safety. How practice‑changing do you consider these results?

IDEOlogy Health avatar
⟳ Misako Nagasaka retweeted
IDEOlogy Health@IDEOlogyHealth·19 Oct 2025

IDEO Xchange: Based on results from BEAMION-1 LUNG-2 cohort 2, which showed a 77% objective response rate and 96% disease control rate in untreated HER2-mutated NSCLC, how likely are you to recommend zongertinib as initial therapy over standard chemotherapy for these patients?

Misako Nagasaka avatar
Misako Nagasaka@MNagasaka·11 Jun 2025

Another option for patients!! On June 11, 2025, the FDA approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive NSCLC. Full prescribing inf for Ibtrozi will be posted on Drugs@FDA.